Evidence map›Paper›PMID 18000087›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2008

Enhancement of muscle mitochondrial function by growth hormone.

Kevin R Short, Niels Moller, Maureen L Bigelow, Jill Coenen-Schimke, K Sreekumaran Nair

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 79 citations in OpenAlex.

  1. Trial
  2. Trial
  3. FNDC5 relates to skeletal muscle IGF-I and mitochondrial function and gene expression in obese men with reduced growth hormone.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2016
    Trial
  4. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.The Journal of clinical endocrinology and metabolism · 2014
    Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. The role of IGF-1 in obesity, cardiovascular disease, and cancer.Medical journal of the Islamic Republic of Iran · 2019
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kevin R ShortEndocrinology Research Unit, Mayo Clinic School of Medicine, 5-194 Joseph, 200 First Street SW, Rochester, Minnesota 55905, USA.
Niels Moller
Maureen L Bigelow
Jill Coenen-Schimke
K Sreekumaran Nair
Mayo Clinic · US

Funding

ZESTRIL VS. VERAPAMIL IN THE TREATMENT OF HYPERTENSIONM01RR000585 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 1985 to 2006
$30.4M
DIABETES AND METABOLISMT32DK007352 · NIDDK · MAYO CLINIC ROCHESTER · PI MICHAEL D. JENSEN · 1986 to 2026
$9.4M
IN VIVO REGULATION OF PROTEIN TURNOVER BY HORMONESR01DK041973 · NIDDK · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI NAIR, K SREEKUMARAN · 1989 to 2014
$7.3M
NCRR NIH HHS M01 RR000585NCRR NIH HHS M01-RR00585NIDDK NIH HHS R01 DK041973NIDDK NIH HHS R01-DK41973NIDDK NIH HHS T32 DK007352NIDDK NIH HHS T32-DK07352
6 · The paper itself

Abstract

contextAlthough GH promotes growth and protein anabolism, which are ATP-dependent processes, the GH effect on mitochondrial regulation remains to be determined.

objectiveOur objective was to determine the acute effect of GH on mitochondrial oxidative capacity in skeletal muscle of healthy subjects. DESIGN AND

settingThe study was a randomized crossover design at an academic medical center.

participantsNine healthy men and women completed the study.

interventionGH (150 microg/h) or saline was infused for 14 h on separate days, and muscle biopsies were obtained.

main outcome measuresOutcome measures included mitochondrial function, gene expression, and protein metabolism.

resultsThe 4-fold increase in plasma GH caused elevations in plasma IGF-I, insulin, glucose, and free fatty acids and a shift in fuel selection, with less carbohydrate (-69%) and leucine (-43%) oxidation and 29% more fat oxidation. Muscle mitochondrial ATP production rate and citrate synthase activity were increased 16-35% in response to GH. GH also resulted in higher abundance of muscle mRNAs encoding IGF-I, mitochondrial proteins from the nuclear (cytochrome c oxidase subunit 4) and mitochondrial (cytochrome c oxidase subunit 3) genomes, the nuclear-derived mitochondrial transcription factor A, and glucose transporter 4. Although GH increased whole-body protein synthesis (nonoxidative disposal of leucine), no effect on synthesis rate of muscle mitochondrial proteins was observed.

conclusionsThese results demonstrate that acute GH action promotes an increase in mitochondrial oxidative capacity and abundance of several mitochondrial genes. These events may occur through direct or indirect effects of GH on intracellular signaling pathways but do not appear to involve a change in mitochondrial protein synthesis rate.

Indexed as

Adenosine TriphosphateAdultBiopsyCitrate (si)-SynthaseCross-Over StudiesFemaleHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleMitochondrial ProteinsMitochondria, MuscleMuscle ProteinsMuscle, SkeletalReverse Transcriptase Polymerase Chain ReactionRNA, MessengerAdenosine TriphosphateCitrate (si)-SynthaseHuman Growth HormoneInsulin-Like Growth Factor IMitochondrial ProteinsMuscle ProteinsRNA, Messenger

Identifiers

PMID18000087
PMCPMC2243230
OpenAlexW2096421773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.